Support teaching, research, and patient care.
The lifetime risk of developing cardiovascular disease (CVD) is determined by the genetic makeup and exposure to modifiable risk factors. The Cardiovascular Link to Environmental ActioN (CLEAN) Lab is interested in understanding how various environmental pollutants (eg. tobacco, e-cigarettes, air pollution and wildfire) interact with genes to affect the transcriptome, epigenome, and eventually disease phenotype of CVD. The current focus is to investigate how different toxic exposures can adversely remodel the vascular wall leading to increased cardiac events. We intersect human genomic discoveries with animal models of disease, in-vitro and in-vivo systems of exposure, single-cell sequencing technologies to solve these questions. Additionally, we collaborate with various members of the Stanford community to develop biomarkers that will aid with detection and prognosis of CVD. We are passionate about the need to reduce the environmental effects on health through strong advocacy and outreach.(http://kimlab.stanford.edu)
A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome
The purpose of this study is to evaluate that milvexian is superior to placebo, in addition
to standard-of-care, in reducing the risk of major adverse cardiovascular event (MACE) (the
composite of cardiovascular [CV] death, myocardial infarction [MI], and ischemic stroke).
View full details
Epicardial Delivery of XC001 Gene Therapy for Refractory Angina Coronary Treatment (The EXACT Trial)
The primary purpose of this trial is to determine the safety of XC001 (AdVEGFXC1) in patients
who suffer from angina caused by coronary artery disease and have no other treatment options.
Subjects in this study will receive one of four intramyocardial doses of XC001 that expresses
human vascular endothelial growth factor (VEGF) which induces therapeutic angiogenesis